9783838375953 - monoamine transporter inhibitors: novel target for drug development di perera, rohan p. (6 risultati)

Taschenbuch. Condizione: Neu. Monoamine Transporter Inhibitors | Novel Target for Drug Development | Rohan P. Perera | Taschenbuch | 164 S. | Englisch | 2010 | LAP LAMBERT Academic Publishing | EAN 9783838375953 | Verantwortliche Person für die EU: preigu GmbH & Co. KG, Lengericher Landstr. 19, 49078 Osnabrück, mail[at]preigu[dot]de | Anbieter: preigu. …

Paperback. Condizione: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Vesicular monoamine transporters (VMAT) are responsible for the uptake of cytosolic monoamines into synaptic vesicles in monoaminergic neurons. In the central nervous system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles. Pharmacologically enhancing DA sequestration by VMAT2, and thus preventing the oxidation of DA, may be a strategy for treating diseases such as Parkinson s disease. The neurotoxicity and addictive properties of various psychostimulants have been attributed, at least partly, to their interference with VMAT2 functions. Therefore, VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse. This book summarizes the possible role of VMAT2 as a therapeutic target and the current understanding of the structure-activity relationship of ligands, including tetrabenazine analogs, ketanserin analogs, and 3-amine-2- phenylpropene with VMAT. The molecular structure of VMAT2 and its relevance to ligand binding and the mechanism of transport of these compounds through VMAT are briefly discussed in this book. 164 pp. Englisch.…

Taschenbuch. Condizione: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Vesicular monoamine transporters (VMAT) are responsible for the uptake of cytosolic monoamines into synaptic vesicles in monoaminergic neurons. In the central nervous system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles. Pharmacologically enhancing DA sequestration by VMAT2, and thus preventing the oxidation of DA, may be a strategy for treating diseases such as Parkinson s disease. The neurotoxicity and addictive properties of various psychostimulants have been attributed, at least partly, to their interference with VMAT2 functions. Therefore, VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse. This book summarizes the possible role of VMAT2 as a therapeutic target and the current understanding of the structure-activity relationship of ligands, including tetrabenazine analogs, ketanserin analogs, and 3-amine-2- phenylpropene with VMAT. The molecular structure of VMAT2 and its relevance to ligand binding and the mechanism of transport of these compounds through VMAT are briefly discussed in this book.…

Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Perera Rohan P.Dr. Rohan P Perera graduated from the University of Colombo with Honours in Chemistry in 1995. He obtained his PhD degrees in Biochemistry, from the Wichita State University in USA. At Present, he is attached to.…

Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Vesicular monoamine transporters (VMAT) are responsible for the uptake of cytosolic monoamines into synaptic vesicles in monoaminergic neurons. In the central nervous system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles. Pharmacologically enhancing DA sequestration by VMAT2, and thus preventing the oxidation of DA, may be a strategy for treating diseases such as Parkinson's disease. The neurotoxicity and addictive properties of various psychostimulants have been attributed, at least partly, to their interference with VMAT2 functions. Therefore, VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse. This book summarizes the possible role of VMAT2 as a therapeutic target and the current understanding of the structure-activity relationship of ligands, including tetrabenazine analogs, ketanserin analogs, and 3-amine-2- phenylpropene with VMAT. The molecular structure of VMAT2 and its relevance to ligand binding and the mechanism of transport of these compounds through VMAT are briefly discussed in this book.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 164 pp. Englisch.…